The DNA-editing technology developer has raised $10m in addition to the $65m it pulled in from investors including Leaps by Bayer in November.
US-based gene editing technology developer Metagenomi added $10m to a series A round featuring chemical and pharmaceutical producer Bayer yesterday, increasing it to $75m.
Investment manager RA Capital Management put up the extra cash and is co-leading the round with Bayer subsidiary Leaps by Bayer and venture capital fund Humboldt Fund. The November 2020 first close also featured Sozo Ventures, Agent Capital, InCube Ventures and HOF Capital.
Founded in 2018 as a spinout of University of California, Berkeley, Metagenomi…
